199 related articles for article (PubMed ID: 31189135)
1. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
[TBL] [Abstract][Full Text] [Related]
2. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer.
Lin SF; Yeh CN; Huang YT; Chou TC; Wong RJ
Cancer Sci; 2021 Feb; 112(2):803-814. PubMed ID: 33306266
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
5. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
[TBL] [Abstract][Full Text] [Related]
7. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
9. Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
Endocr Relat Cancer; 2018 Oct; 25(10):853-864. PubMed ID: 29895526
[TBL] [Abstract][Full Text] [Related]
10. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
[TBL] [Abstract][Full Text] [Related]
15. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
